SAB Biotherapeutics, Inc.
SABS
$3.67
$0.030.82%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 110.88M | 5.71M | 12.85M | 20.76M | 30.40M |
| Total Receivables | 560.00K | -- | 21.40K | 55.00K | 97.00K |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 1.84M | 3.59M | 3.43M | 2.98M | 2.04M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 113.28M | 9.31M | 16.30M | 23.79M | 32.54M |
|
|
|||||
| Total Current Assets | 113.28M | 9.31M | 16.30M | 23.79M | 32.54M |
| Net Property, Plant & Equipment | 19.44M | 20.40M | 21.37M | 19.92M | 20.75M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 124.10K | 417.50K | 449.80K | 482.10K | 514.40K |
| Total Assets | 183.45M | 30.13M | 38.12M | 44.20M | 53.80M |
|
|
|||||
| Total Accounts Payable | 2.96M | 2.62M | 2.52M | 1.69M | 1.30M |
| Total Accrued Expenses | 6.85M | 7.09M | 6.06M | 5.47M | 6.88M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 988.30K | 963.20K | 1.08M | 811.80K | 524.70K |
| Total Finance Division Other Current Liabilities | -- | -- | -- | -- | 114.70K |
| Total Other Current Liabilities | -- | -- | -- | -- | 114.70K |
| Total Current Liabilities | 10.79M | 10.68M | 9.65M | 7.98M | 8.82M |
|
|
|||||
| Total Current Liabilities | 10.79M | 10.68M | 9.65M | 7.98M | 8.82M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 5.20M | 5.46M | 5.71M | 3.86M | 4.00M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 2.38M | 1.98M | 1.35M | 6.39M | 4.08M |
| Total Liabilities | 18.37M | 18.11M | 16.71M | 18.23M | 16.89M |
|
|
|||||
| Common Stock & APIC | 264.56M | 157.03M | 156.41M | 155.80M | 155.15M |
| Retained Earnings | -94.03M | -139.48M | -129.37M | -124.17M | -112.77M |
| Treasury Stock & Other | -5.45M | -5.54M | -5.63M | -5.66M | -5.47M |
| Total Common Equity | 165.07M | 12.02M | 21.41M | 25.97M | 36.90M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
|
|||||
| Total Common Equity | 165.07M | 12.02M | 21.41M | 25.97M | 36.90M |
| Total Preferred Equity | 100.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 165.07M | 12.02M | 21.41M | 25.97M | 36.90M |
|
|
|||||